2023
Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System
Kinslow C, Rae A, Kumar P, McKhann G, Sisti M, Bruce J, Yu J, Cheng S, Wang T. Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System. Cancers 2023, 15: 876. PMID: 36765837, PMCID: PMC9913704, DOI: 10.3390/cancers15030876.Peer-Reviewed Original ResearchNational Cancer DatabaseCause-specific survivalIntermediate-risk groupCentral nervous systemSolitary fibrous tumor/hemangiopericytomaAssociation of radiotherapyHigh-risk groupOverall survivalRisk categoriesRisk stratificationAssociated with improved survivalPrognostic risk categoriesGross-total resectionKaplan-Meier methodNervous systemCox proportional hazards regressionLow-risk groupProportional hazards regressionEORTC Cooperative GroupRadiotherapy strategiesSEER databaseSurvival benefitProspective trialsCancer DatabaseMeningeal tumors
2012
The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population.
Quon J, Yu J, Soulos P, Gross C. The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population. Journal Of Clinical Oncology 2012, 30: e15150-e15150. DOI: 10.1200/jco.2012.30.15_suppl.e15150.Peer-Reviewed Original ResearchHigh-risk groupShort life expectancyRisk groupsProstate cancerLife expectancyNational Comprehensive Cancer Network guidelinesAndrogen deprivation therapy useConcurrent androgen deprivation therapyEnd Results-Medicare databaseAndrogen deprivation therapyLow-risk cancersExternal beam radiationLow-risk groupLonger life expectancyDeprivation therapyNCCN guidelinesOlder patientsClinical factorsTherapy useGuideline recommendationsTumor characteristicsNetwork guidelinesCancer characteristicsRadiation therapyMedicare population